Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 7 consecutive quarters of double digit growth. Click here to learn more ›

Bremelanotide for Hypoactive Sexual Desire Disorder: Analyses From a Phase 2B Dose‐Ranging Study

Leave a Reply

Scroll to Top